BostonGene Showcases AI Disease Modeling at JSMO 2026 to Advance Precision Oncology
BostonGene is set to highlight the capabilities of its advanced disease modeling platform at the 23rd Annual Meeting of the Japanese Society of Medical Oncology (JSMO 2026), taking place from March 26–28, 2026, in Yokohama. The company’s participation reflects its growing influence in the field of precision oncology and its expanding collaborations with leading biopharmaceutical organizations worldwide.
The annual JSMO meeting is widely regarded as one of the most prominent oncology conferences in Asia, drawing more than 7,000 experts from across the globe. It serves as a platform for clinicians, researchers, and industry leaders to exchange insights on the latest advancements in cancer research, clinical practices, and emerging technologies. A central theme of this year’s conference is the integration of cutting-edge scientific evidence into real-world clinical applications, with particular emphasis on cancer genomics, multidisciplinary care, and the transformative role of artificial intelligence in oncology.
BostonGene’s presence at the event underscores its commitment to advancing AI-driven solutions that bridge the gap between complex biological data and actionable clinical insights. The company is recognized for developing a sophisticated AI foundation model designed to analyze tumor and immune system interactions at a systems level. This platform goes beyond traditional approaches that rely on isolated biomarkers, instead offering a comprehensive view of disease biology by integrating multiple layers of data.
At JSMO 2026, BostonGene will present research demonstrating how its platform enables disease-level modeling through the integration of multimodal datasets. These datasets include electronic medical records, genomic sequencing data, transcriptomic profiles, medical imaging, and immune system characterization. By combining these diverse data sources, the platform constructs a holistic representation of the biological system underlying each patient’s disease.
This systems-level approach allows for deeper insights into how cancers develop, progress, and respond to treatment. Rather than analyzing individual variables in isolation, BostonGene’s model identifies complex patterns and interactions within the data, generating what the company describes as “decision-grade insights.” These insights are designed to support both drug development and clinical decision-making processes.
One of the key applications of BostonGene’s platform is its ability to predict patient responses to therapies. By analyzing molecular and clinical data, the model can forecast how a patient is likely to respond to a specific treatment, including the potential for resistance or adverse effects. This predictive capability is particularly valuable in oncology, where treatment outcomes can vary widely between patients.
In addition to predicting treatment responses, the platform also supports patient stratification for clinical trials. Identifying the right patients for a given study is a critical factor in the success of clinical trials, especially in oncology where targeted therapies are increasingly common. BostonGene’s model helps researchers identify patient subgroups that are most likely to benefit from specific investigational therapies, improving trial efficiency and increasing the likelihood of successful outcomes.
The platform also plays a role in informing therapeutic strategies, including the development of combination treatments. By understanding how different biological pathways interact, researchers can design more effective treatment regimens that target multiple aspects of the disease simultaneously. This is particularly important in cancer treatment, where combination therapies are often necessary to overcome resistance and achieve durable responses.
BostonGene’s technology is already being applied in collaborations with major biopharmaceutical companies. These partnerships typically begin with focused pilot projects aimed at addressing specific research questions or clinical challenges. Over time, successful pilots often expand into broader integrations of the platform across multiple programs, reflecting the value and scalability of BostonGene’s approach.
Another notable feature of the platform is its adaptability. While it is currently focused on oncology, the underlying modeling framework can be extended to other disease areas through additional training. This means that the core architecture does not need to be rebuilt for each new application, allowing for efficient expansion into other therapeutic domains such as immunology, neurology, or metabolic diseases.
As part of its participation at JSMO 2026, BostonGene will deliver both a symposium presentation and a poster presentation, showcasing different aspects of its technology and research.
The symposium presentation, titled “The integration of genomic profiling with AI is transforming therapeutic decision-making in Oncology/Hematology,” will take place on Thursday, March 26, from 16:05 to 18:05. The session will be held in Room 4 (G5, 1F) at Pacifico Yokohama North. The presentation will be delivered by Alexander Bagaev, PhD, who will discuss how AI-driven genomic analysis is reshaping treatment strategies in oncology and hematology.
In addition to the symposium, BostonGene will present a poster titled “Validation of BostonGene Tumor Portrait Assay for Comprehensive Genomic and Transcriptomic Profiling in Diverse Cohorts.” This poster, designated as P014-2, will be presented on Thursday, March 26, from 13:05 to 13:50 in the Poster Room located in Exhibition Hall D at Pacifico Yokohama North. The presentation will be delivered by Zlata Polyakova, PhD, representing BostonGene Japan.
The Tumor Portrait Assay highlighted in the poster is a key component of BostonGene’s platform. It combines genomic and transcriptomic profiling to provide a detailed characterization of tumors, enabling more precise classification and treatment planning. The validation of this assay across diverse patient cohorts demonstrates its robustness and potential for widespread clinical application.
Overall, BostonGene’s participation at JSMO 2026 reflects a broader trend in oncology toward the integration of artificial intelligence and big data analytics into both research and clinical practice. As the volume and complexity of biomedical data continue to grow, platforms like BostonGene’s are becoming increasingly essential for extracting meaningful insights and translating them into improved patient outcomes.
By leveraging its AI foundation model, BostonGene aims to accelerate drug development, enhance clinical trial design, and support more personalized treatment strategies. Its work at JSMO 2026 not only highlights the current capabilities of its platform but also points to the future of precision medicine, where data-driven decision-making plays a central role in advancing cancer care and beyond.
About BostonGene Corporation
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s foundation model for tumor and immune biology integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation
About BostonGene Japan
BostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene’s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient.
